TL;DR
This study reveals how rapamycin protects the heart in autoimmune myocarditis by reprogramming inflammatory macrophages. It identifies a specific pathway (mTORC1-C/EBPβ-OSM) that drives macrophage dysfunction and subsequent heart damage, offering a promising therapeutic target.
What Problem Does This Paper Address?
Autoimmune myocarditis is a serious condition where the immune system attacks the heart, potentially leading to chronic heart failure. While treatments exist for the acute phase, many patients develop long-term issues due to persistent inflammation and heart damage. The exact mechanisms driving this chronic phase, particularly how immune cells like macrophages contribute to ongoing cardiac injury, are not fully understood. This leaves a critical need for targeted therapies that can prevent the transition from acute myocarditis to chronic inflammatory cardiomyopathy.
Methods
The researchers used a mouse model of autoimmune myocarditis (EAM) induced by a-myosin heavy chain immunization. They then treated these mice with rapamycin, an mTORC1 inhibitor, during the inflammatory phase. To understand the cellular and molecular changes, they employed a multi-pronged approach:
- Echocardiography and Millar Catheterization: To assess cardiac function and hemodynamics.
- Histology (H&E and Sirius Red staining): To evaluate inflammation and fibrosis in heart tissue.
- ELISA and RT-qPCR: To measure levels of inflammatory cytokines and gene expression.
- Single-cell RNA sequencing (scRNA-seq): This was a key technique, allowing them to analyze the gene expression of individual immune cells within the heart. They used advanced bioinformatics tools like UMAP for visualization, GO enrichment analysis for functional interpretation, AUCell for pathway scoring, and Monocle 3 for pseudotime trajectory analysis to understand cell differentiation.
- Seahorse Metabolic Assays: To measure the metabolic activity (glycolysis, oxidative phosphorylation) of isolated cardiac macrophages.
- Western Blotting: To assess protein levels and phosphorylation states (e.g., mTOR, S6, C/EBPβ).
- Co-immunoprecipitation: To confirm protein-protein interactions (e.g., C/EBPβ and Raptor).
- In vitro Co-culture Systems: Using bone marrow-derived macrophages (BMDMs) and cardiomyocytes to study cell-cell communication.
- In vivo OSM Neutralization: Administering an antibody to block the action of Oncostatin M (OSM) to validate its role.
Datasets
The study utilized scRNA-seq data generated from cardiac CD45+ immune cells isolated from four groups of mice: Control (Con), Rapamycin-treated (Rap), EAM, and EAM + Rapamycin. This dataset was analyzed using various computational tools to identify cell types, their proportions, gene expression patterns, and functional pathways.
Key Insights and Ideas
- Rapamycin's Broad Impact: Rapamycin doesn't just broadly suppress inflammation; it specifically reprograms key immune cells (macrophages) in the heart, shifting them from a pro-inflammatory to a less harmful state.
- Macrophage Heterogeneity is Crucial: The heart's immune landscape is complex. The study identified distinct macrophage subsets, with Cxcl9+ macrophages emerging as the primary drivers of inflammation and damage in this model.
- The mTORC1-C/EBPβ-OSM Axis: This is the central mechanistic discovery. Rapamycin inhibits mTORC1, which in turn suppresses C/EBPβ. This transcription factor is critical for the development and inflammatory programming of Cxcl9+ macrophages. These macrophages then release OSM, which directly harms cardiomyocytes.
- OSM as a Key Mediator: Oncostatin M (OSM) is identified as a critical signaling molecule from inflammatory macrophages to cardiomyocytes, impairing their metabolism and contractility.
- Therapeutic Potential of OSM Blockade: Blocking OSM with an antibody in vivo replicated many of rapamycin's protective effects, highlighting OSM as a viable therapeutic target.
Key Results
- Rapamycin Preserves Cardiac Function: In EAM mice, rapamycin treatment significantly improved ejection fraction, fractional shortening, stroke volume, and cardiac output, and improved hemodynamic parameters.
- Reduced Inflammation and Fibrosis: Histological analysis showed marked reductions in inflammatory cell infiltration and collagen deposition in rapamycin-treated EAM hearts.
- Macrophage Reprogramming: scRNA-seq revealed that rapamycin reduced the expansion of monocyte-macrophages in EAM hearts and shifted their metabolic profile from glycolysis towards oxidative phosphorylation.
- Cxcl9+ Macrophages are Pathogenic: These macrophages were significantly expanded in EAM and showed high inflammatory and glycolytic activity. Rapamycin treatment attenuated these features.
- C/EBPβ Drives Pathogenic Macrophage Fate: C/EBPβ was identified as a key regulator of Cxcl9+ macrophage differentiation and inflammatory programming, and its activity was suppressed by rapamycin.
- OSM Mediates Macrophage-Cardiomyocyte Crosstalk: Macrophage-derived OSM impaired cardiomyocyte metabolism and contractility in vitro, and this effect was reversed by OSM neutralization.
- OSM Blockade Mimics Rapamycin's Benefits: In vivo OSM neutralization in EAM mice improved cardiac function, reduced inflammation and fibrosis, and lowered injury markers.
Limitations and Future Work
- Model Limitations: The EAM mouse model, while useful, doesn't fully capture the diverse etiologies of human myocarditis (e.g., viral, immune checkpoint inhibitor-associated).
- Pleiotropic Effects of Rapamycin: Rapamycin has broad effects, and while the study focused on mTORC1, contributions from mTORC2 or other pathways cannot be entirely ruled out. Future work could systematically investigate mTORC2 markers.
- Necessity of C/EBPβ: While gain-of-function experiments for C/EBPβ were performed, loss-of-function studies (e.g., conditional knockout) are needed to definitively establish its necessity in vivo.
- OSM's Dual Role: The paper notes OSM's context-dependent effects. Future research could explore titrated OSM overexpression in control and EAM models to better define its therapeutic window and potential for direct cardiac benefit.
- Systemic Immunosuppression: While targeting the mTORC1-C/EBPβ-OSM axis offers disease specificity, further studies are needed to define optimal dosing and timing to minimize systemic immunosuppression.
Summary updated